Here at the Janssen Health Policy Centre
our mission is to raise awareness on issues impacting healthcare policy, build
consensus through dialogue, and shape recommendations for future policies

Report-14/02/2017
The Case of Blood Cancer: Innovation and the Economics of Healthcare

While innovation is central for the quality of healthcare and improving health outcomes, it is also a source of increasing costs for governments. Confronted by fiscal pressures, governments have made efforts to restrict access to innovative treatments. While such policies are understandable, they are not necessarily supportive of the ambition to control the cost burden of a disease. This paper reviews economic analyses of the cost burden of cancer, and blood cancers in particular, and the effects that innovative treatments have on other sources of costs in the healthcare system or the economy as a whole. Janssen recently sponsored the European Centre for International Political Economy (ECIPE) summit.

download

The Case of Blood Cancer: Innovation and the Economics of Healthcare

While innovation is central for the quality of healthcare and improving health outcomes, it is also a source of increasing costs for governments. Confronted by fiscal pressures, governments have made efforts to restrict access to innovative treatments. While such policies are understandable, they are not necessarily supportive of the ambition to control the cost burden of a disease. This paper reviews economic analyses of the cost burden of cancer, and blood cancers in particular, and the effects that innovative treatments have on other sources of costs in the healthcare system or the economy as a whole.

Janssen recently sponsored the European Centre for International Political Economy (ECIPE) summit.

Download the report

Blood Cancers

Cancers affecting the blood, bone marrow and lymphatic system

Download the infographic


Chronic Lymphocytic Leukaemia (CLL)

CLL is generally a slow growing blood cancer that originates from B cells, a type of white blood cell (lymphocyte)

Download the infographic


Mantle Cell Lymphoma (MCL)

MCL affects the lymphatic system and is an aggressive form of blood cancer which originates from B cells, a type of white blood cell (lymphocyte)

Download the infographic


Relapsed and Refractory Multiple Myeloma

Multiple Myeloma (MM) is an incurable blood cancer that starts in the bone marrow and is characterised by an excessive profilation of plasma cells.

Download the infographic


Waldenström’s Macroglobulinemia (WM)

Waldenström’s macroglobulinemia (WM), pronounced ‘val-den-strem’, is named after Swedish physician Jan Gösta Waldenström, who first described the disease’s clinical features. It is a slow-growing and rare type of blood cancer that originates from B cells, a type of white blood cell (lymphocyte) that develops in the bone marrow.

Download the infographic

Acute Myeloid Leukaemia (AML)

Acute myeloid leukaemia (AML) is an aggressive form of blood cancer and is characterised by a rapid and excessive production of abnormal cells derived from the bone marrow.

Download the infographic

Myelodysplastic Syndromes (MDS)

Myelodysplastic syndromes (MDS) are a group of bone marrow disorders in which the bone marrow does not produce enough healthy blood cells.

Download the infographic

Related News


The Case of Blood Cancer: Innovation

While innovation is central for the quality of healthcare and improving health outcomes, it is also a source of increasing costs for governments. Confronted by fiscal pressures, governments have made efforts to restrict access to innovative treatments. While such policies are understandable, they are not necessarily supportive of the ambition to control the cost burden of a disease. This paper reviews economic analyses of the cost burden of cancer, and blood cancers in particular, and the effects that innovative treatments have on other sources of costs in the healthcare system or the economy as a whole. Janssen recently sponsored the European Centre for International Political Economy (ECIPE) summit.

14/02/2017 Find out more

Report archive